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Introduction
The Committee for Japanese Standards for Antimicrobial
Susceptibility Testing for Bacteria, Japan Society of
Chemotherapy, proposed clinical breakpoints for antimi-
crobial agents which could be used in pulmonary infections
and sepsis at the 41st All Japan Meeting of the Japan Soci-
ety of Chemotherapy (Tokyo, 1993), soliciting opinions
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from the members of the Society. Thereafter, the originally
proposed breakpoints were partially revised, and the com-
mittee submitted the breakpoints in pulmonary infections
and sepsis as authorized by the Japan Society of Chemo-
therapy.1,2
Since the above meeting in 1993, many antimicrobial
agents have been newly developed year after year and some
of them have become available in clinically. Here we pro-
pose clinical breakpoints for 15 antimicrobial agents (six
cephems, three carbapenems, two penems, three new
quinolones, and one macrolide), which have been released
since the previous reports were published. For agents for
which the results of clinical double-blind tests were ob-
tained, the breakpoints calculated, based upon the formula
shown in Table 1 were assessed in relation to the clinical
response and consistently modiﬁed. Also, for three already
released agents, for which the breakpoints had not
been analyzed due to lack of basic data at the time of the
original reports we added supplemental information in this
report.
Clinical breakpoints for new agents in
pulmonary infections
Cephems
We attempted to analyze the breakpoints for six cephem
agents, cefpirome (CPR; HR-810), cefepime (CFPM;
BMY-28142), cefclidin (CFCL; E-1040), cefozopran
(CZOP; SCE-2787), ceﬂuprenam (CFLP; E-1077), and
cefoselis (CFSL; FK-037). The breakpoints for each agent
were determined, based upon the calculation formula
shown in Table 1, and we subsequently assessed these in
relation to the clinical response in each infection and the
minimum inhibitory concentration (MIC) against the caus-
ative organisms isolated. No remarkable difference in the
breakpoint for each agent was recognized; therefore, the
breakpoints for acute pneumonia and chronic respiratory
tract infections were proposed as 4.0μg/ml and 2.0μg/ml,
respectively (Table 2).
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breakpoints were reported as those for cefcamate pivoxil
(CCMT-PI) in 1994. The single therapeutic dose has also
changed, from 200 to 100 mg; therefore the breakpoints for
100mg are shown (in Table 2).
Carbapenems
Since the human pharmacokinetics are similar among
panipenem/betamipron (PAPM/BP; CS-976), meropenem
(MEPM; SM-7338), and biapenem (BIPM; L-627), the
breakpoints for acute pneumonia and chronic pulmonary
tract infections were proposed as 2.0μg/ml and 1.0μg/ml,
respectively, based upon the calculation formula and the
clinical response. The breakpoints for imipenem/cilastatin
(IPM/CS) were identical with those of the three other
carbapenems, as the in pharmacokinetics and clinical re-
sponses were almost the same. In the previous reports, they
had been 1.0μg/ml and 0.5μg/ml, respectively, due to the
T1/2 (the terminal half-life of the drug) being a little shorter
than 1h.
Penems
Breakpoints for faropenem (FRPM; SY-5555) in acute
pneumonia and chronic respiratory tract infections were
settled as 0.5μg/ml and 0.25μg/ml, respectively, because its
clinical and bacterial response were not as effective as the
Table 1. Calculation formula for breakpoints
Breakpoint MIC  Cm  t  Rtr  A
where Cm is a factor determined by Cmax;
32: Cmax  400μg/ml
16: 200  Cmax  400
8: 50  Cmax  200
4: 10  Cmax  50
2: 1  Cmax  10
1: Cmax  1
t is a factor allowing for half-life differences;
1: T1/2  3h
0.5: 1  T1/2  3
0.25: T1/2  1
Rtr is a factor dependent on the ratio R ( maximum
concentration at the site/Cmax ratio);
4: R  10
2: 1.2  R  10
1: 0.12  R  1.2
0.5: 0.012  R  0.12
0.25: R  0.012
A is a factor which takes into account the antimicrobial
characteristics;
2: aminoglycosides
1: beta-lactams (penicillins, cephems, monobactams,
carbapenems) and new quinolones
0.5: tetracyclines, macrolides, clindamycins,
polypeptides
Table 2. Clinical breakpoints for new antimicrobial agents in pulmonary infections
Group Drug Route Dose (single) Breakpoint MIC
(μg/ml)
Pneumonia CRTIa
Cephems
Cefpirome (CPR) i.v. 1 g 4 2
Cefepime (CFPM) i.v. 1 g 4 2
Cefclidin (CFCL) i.v. 1 g 4 2
Cefozopran (CZOP) i.v. 1 g 4 2
Ceﬂuprenam (CFLP) i.v. 1 g 4 2
Cefoselis (CFSL) i.v. 1 g 4 2
Cefcapene pivoxilb (CFPN-PI) p.o. 100 mg 0.5d 0.25d
Carbapenems
Imipenem/cilastatin (IPM/CS) i.v. 500 mg 2d 1d
Panipenem/betamipron (PAPM/BP) i.v. 500 mg 2 1
Meropenem (MEPM) i.v. 500 mg 2 1
Biapenem (BIPM) i.v. 300 mg 2 1
Penems
Faropenem (FRPM) p.o. 300 mg 0.5 0.25c
Ritipenem acoxil (RIPM-AC) p.o. 200 mg 0.5 0.125
New quinolones
Grepaﬂoxacin (GPFX) p.o. 200 mg 1 2
Pazuﬂoxacin (PZFX) p.o. 200 mg 1 1
Pruliﬂoxacine (PUFX) p.o. 300 mg 2 2
Macrolide
Azithromycin (AZM) p.o. 500 mg 1 2
MIC, Minimum inhibitory concentration
a Chronic respiratory tract infection
b Drug name and abbreviation changed since previous reports
c Medical expense insurance not available in Japan for this indication
d Determined after reexamination
e Tentative; further studies needed
For cefcapene pivoxil (CFPN-PI; S-1108), released in
1997, the breakpoints are given again in this report because
its drug name and abbreviation have been changed since its
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calculated values. In Japan, there is no medical expense
insurance for this agent when it is used for chronic respira-
tory tract infections.
As the calculated values and the clinical response were
correlated for ritipenem acoxil (RIPM-AC; FC/TA-891),
breakpoints of 0.5μg/ml and 0.125μg/ml were proposed for
acute pneumonia and chronic respiratory tract infections,
respectively, according to the formula.
New quinolones
For grepaﬂoxacin (GPFX; OPC-17116) and pazuﬂoxacin
(PZFX; T-3761), the calculated breakpoints were proposed,
as the calculated values and the clinical response data were
correlative. The breakpoints for pruliﬂoxacin (PUFX; NM
441) were calculated and proposed tentatively based upon
the data for 200 or 500 mg of the agent administered orally.
Because the number of clinical cases and data for a single
300-mg clinical therapeutic dose for pulmonary infections
were insufﬁcient, further detailed study of this agent’s phar-
macokinetics should be carried out.
Macrolides
Azithromycin (AZM; CP-62, 993) exhibits unique pharma-
cokinetics differing from any other agent, as its T1/2 over 24h
indicates. A tentative breakpoint was proposed, as the clini-
cal data were taken into account, but further study is
required.
Table 3. Clinical breakpoints for new antimicrobial agents in sepsis
Group Drug Route Dose (single) Breakpoint MIC (μg/ml)
Cephems
Cefpirome (CPR) i.v. 1 g 2
Cefepime (CFPM) i.v. 1 g 2
Cefclidin (CFCL) i.v. 1 g 2
Cefozopran (CZOP) i.v. 1 g 2
Ceﬂuprenam (CFLP) i.v. 1 g 2
Cefoselis (CFSL) i.v. 1 g 2
Carbapenems
Imipenem/cilastatin (IPM/CS) i.v. 500 mg 1a
Panipenem/betamipron (PAPM/BP) i.v. 500 mg 1
Meropenem (MEPM) i.v. 500 mg 1
Biapenem (BIPM) i.v. 300 mg 1
a Determined after reexamination
Table 4. Clinical breakpoints for antimicrobial agents (supplemental)
Group Drug Route Dose (single) Breakpoint MIC (μg/ml)
Pneumonia CRTIa Sepsis
Macrolide EM i.v. 500mg 1 1 –
EM p.o. 200mg 0.5 0.5 –
Lincomycin CLDM i.v. 600mg 0.5 0.5 –
Polypeptide VCM i.v. 500mg 2 1b 1
EM, Erythromycin; CLDM, Clindamycin; VCM, Varcomycin
a Chronic respiratory tract infection
b Medical expense insurance not available in Japan for this indication
Clinical breakpoints for new agents in sepsis
Of the 15 new antimicrobial agents, breakpoints for six
cephems and three carbapenems, given intravenously in
sepsis were proposed. The breakpoints for each agent
(Table 3) were determined based upon the formula given in
Table 1. The proposed breakpoint for IPM/CS in sepsis was
the same value as that for the other carbapenems, as ex-
plained for pulmonary infections.
Clinical breakpoints for antimicrobial
agents (supplemental)
Breakpoints for erythromycin (EM), clindamycin (CLDM),
and vancomycin (VCM) were investigated and proposed
(Table 4), as they could not be determined in the previous
reports due to the lack of basic data.
Closing remarks
Lastly, it only remains to be stated that there have been
some minor changes in the therapeutic single dose for a
considerable number of antimicrobial agents since their re-
lease. Therefore, because of insufﬁcient or uncertain data,
further studies of the pharmacokinetics and the clinical re-
sponses of those agents are needed.
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